Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

被引：0
作者：
Marcelo Madeira
André Mattar
Ângela Flávia Logullo
Fernando Augusto Soares
Luiz Henrique Gebrim
机构：
[1] Federal University of Sao Paulo-UNIFESP,Senology Discipline, Department of Gynecology
[2] Department of Obstetrics & Gynecology and Women’s Health of Albert Einstein Hospital,Department of Breast Medical Oncology
[3] Centro de Referência da Saúde da Mulher (CRSM)-Pérola Byington Hospital,Department of Pathology
[4] Federal University of Sao Paulo-UNIFESP,Department of Pathology, AC Camargo Hospital
[5] R. Professor Antonio Prudente,undefined
[6] 211,undefined
来源：
BMC Cancer | / 13卷
关键词：
Estrogen receptor beta; Breast cancer; Estrogen receptor; Aromatase inhibitors/Anastrozole; Tamoxifen; Ki67; Neoadjuvant therapy; Tumor markers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 325 条
[1]  
Bray F(2004)The changing global patterns of female breast cancer incidence and mortality Breast Cancer Res 6 229-239
[2]  
McCarron P(2007)Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women Breast Cancer Res 9 R28-1717
[3]  
Parkin DM(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-2397
[4]  
Jemal A(2008)Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions Cancer 113 2385-406
[5]  
Ward E(2004)A review of adjuvant hormonal therapy in breast cancer Endocr Relat Cancer 11 391-22
[6]  
Thun MJ(2004)The biological role of estrogen receptors alpha and beta in cancer Crit Rev Oncol Hematol 50 3-604
[7]  
Hurvitz SA(2002)Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression Am J Pathol 160 597-62
[8]  
Pietras RJ(2005)Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer Lancet 365 60-5930
[9]  
Jones KL(1996)Cloning of a novel receptor expressed in rat prostate and ovary Proc Natl Acad Sci U S A 93 5925-1051
[10]  
Buzdar AU(2008)ERbeta in breast cancer–onlooker, passive player, or active protector? Steroids 73 1039-1571
12345678910